BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

4830 related articles for article (PubMed ID: 15592017)

  • 21. Tumour-stroma interactions between metastatic prostate cancer cells and fibroblasts.
    Kaminski A; Hahne JC; Haddouti el-M; Florin A; Wellmann A; Wernert N
    Int J Mol Med; 2006 Nov; 18(5):941-50. PubMed ID: 17016625
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of tumor microenvironment in prostate cancer bone metastasis.
    Morrissey C; Vessella RL
    J Cell Biochem; 2007 Jul; 101(4):873-86. PubMed ID: 17387734
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Breast cancer invasion: the key role of normal cells of host tissues].
    Foidart JM; Polette M; Birembaut P; Noel A
    Bull Acad Natl Med; 1994 Mar; 178(3):533-42; discussion 542-4. PubMed ID: 8076190
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling.
    Tuxhorn JA; Ayala GE; Smith MJ; Smith VC; Dang TD; Rowley DR
    Clin Cancer Res; 2002 Sep; 8(9):2912-23. PubMed ID: 12231536
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modulation of prostate cancer growth in bone microenvironments.
    Edlund M; Sung SY; Chung LW
    J Cell Biochem; 2004 Mar; 91(4):686-705. PubMed ID: 14991761
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A paradigm for the treatment of prostate cancer bone metastases based on an understanding of tumor cell-microenvironment interactions.
    Loberg RD; Gayed BA; Olson KB; Pienta KJ
    J Cell Biochem; 2005 Oct; 96(3):439-46. PubMed ID: 15988761
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression.
    Lee SO; Chun JY; Nadiminty N; Lou W; Gao AC
    Prostate; 2007 May; 67(7):764-73. PubMed ID: 17373716
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Secreted frizzled-related protein 4 inhibits proliferation and metastatic potential in prostate cancer.
    Horvath LG; Lelliott JE; Kench JG; Lee CS; Williams ED; Saunders DN; Grygiel JJ; Sutherland RL; Henshall SM
    Prostate; 2007 Jul; 67(10):1081-90. PubMed ID: 17476687
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Three-dimensional co-culture models to study prostate cancer growth, progression, and metastasis to bone.
    Wang R; Xu J; Juliette L; Castilleja A; Love J; Sung SY; Zhau HE; Goodwin TJ; Chung LW
    Semin Cancer Biol; 2005 Oct; 15(5):353-64. PubMed ID: 15982899
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting bone metastasis in prostate cancer with endothelin receptor antagonists.
    Carducci MA; Jimeno A
    Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6296s-6300s. PubMed ID: 17062717
    [TBL] [Abstract][Full Text] [Related]  

  • 31. DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process.
    Mori K; Le Goff B; Charrier C; Battaglia S; Heymann D; RĂ©dini F
    Bone; 2007 Apr; 40(4):981-90. PubMed ID: 17196895
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic potential of curcumin in prostate cancer--V: Interference with the osteomimetic properties of hormone refractory C4-2B prostate cancer cells.
    Dorai T; Dutcher JP; Dempster DW; Wiernik PH
    Prostate; 2004 Jun; 60(1):1-17. PubMed ID: 15129424
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fascin regulates prostate cancer cell invasion and is associated with metastasis and biochemical failure in prostate cancer.
    Darnel AD; Behmoaram E; Vollmer RT; Corcos J; Bijian K; Sircar K; Su J; Jiao J; Alaoui-Jamali MA; Bismar TA
    Clin Cancer Res; 2009 Feb; 15(4):1376-83. PubMed ID: 19228738
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gene promoter methylation in prostate tumor-associated stromal cells.
    Hanson JA; Gillespie JW; Grover A; Tangrea MA; Chuaqui RF; Emmert-Buck MR; Tangrea JA; Libutti SK; Linehan WM; Woodson KG
    J Natl Cancer Inst; 2006 Feb; 98(4):255-61. PubMed ID: 16478744
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Decreased expression of E-cadherin in the progression of rat prostatic cancer.
    Bussemakers MJ; van Moorselaar RJ; Giroldi LA; Ichikawa T; Isaacs JT; Takeichi M; Debruyne FM; Schalken JA
    Cancer Res; 1992 May; 52(10):2916-22. PubMed ID: 1581909
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CL1-GFP: an androgen independent metastatic tumor model for prostate cancer.
    Patel BJ; Pantuck AJ; Zisman A; Tsui KH; Paik SH; Caliliw R; Sheriff S; Wu L; deKernion JB; Tso CL; Belldegrun AS
    J Urol; 2000 Oct; 164(4):1420-5. PubMed ID: 10992426
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stromal anti-apoptotic androgen receptor target gene c-FLIP in prostate cancer.
    Ye H; Li Y; Melamed J; Pearce P; Wei J; Chiriboga L; Wang Z; Osman I; Lee P
    J Urol; 2009 Feb; 181(2):872-7. PubMed ID: 19095249
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Smad3 is overexpressed in advanced human prostate cancer and necessary for progressive growth of prostate cancer cells in nude mice.
    Lu S; Lee J; Revelo M; Wang X; Lu S; Dong Z
    Clin Cancer Res; 2007 Oct; 13(19):5692-702. PubMed ID: 17908958
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression and role of Foxa proteins in prostate cancer.
    Mirosevich J; Gao N; Gupta A; Shappell SB; Jove R; Matusik RJ
    Prostate; 2006 Jul; 66(10):1013-28. PubMed ID: 16001449
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: a stem cell model.
    Bonkhoff H; Remberger K
    Prostate; 1996 Feb; 28(2):98-106. PubMed ID: 8604398
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 242.